169 related articles for article (PubMed ID: 30312607)
1. Clinicopathologic Features of Thymoma With the Expression of Programmed Death Ligand 1.
Hakiri S; Fukui T; Mori S; Kawaguchi K; Nakamura S; Ozeki N; Kato T; Goto M; Yatabe Y; Yokoi K
Ann Thorac Surg; 2019 Feb; 107(2):418-424. PubMed ID: 30312607
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma.
Yokoyama S; Miyoshi H; Nishi T; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Kakuma T; Ohshima K
Ann Thorac Surg; 2016 Apr; 101(4):1361-9. PubMed ID: 26794891
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature.
Guleria P; Husain N; Shukla S; Kumar S; Parshad R; Jain D
Ann Diagn Pathol; 2018 Jun; 34():135-141. PubMed ID: 29661720
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression level in different thymoma stages and thymic carcinoma: a meta-analysis.
Chen HF; Wu LX; Li XF; Zhu YC; Pan WW; Wang WX; Xu CW; Huang JH; Wu MH; Du KQ
Tumori; 2020 Aug; 106(4):306-311. PubMed ID: 32366210
[TBL] [Abstract][Full Text] [Related]
5. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA
J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286
[TBL] [Abstract][Full Text] [Related]
6. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
7. Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma.
Wei YF; Chu CY; Chang CC; Lin SH; Su WC; Tseng YL; Lin CC; Yen YT
Lung Cancer; 2018 Nov; 125():35-42. PubMed ID: 30429036
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach.
Berardi R; Goteri G; Brunelli A; Pagliaretta S; Paolucci V; Caramanti M; Rinaldi S; Refai M; Pompili C; Morgese F; Torniai M; Marcantognini G; Ricci G; Mazzanti P; Onofri A; Bianchi F; Sabbatini A; Cascinu S
Expert Opin Ther Targets; 2020 Sep; 24(9):937-943. PubMed ID: 32662701
[TBL] [Abstract][Full Text] [Related]
9. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
Marchevsky AM; Walts AE
Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
[TBL] [Abstract][Full Text] [Related]
10. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.
Weissferdt A; Fujimoto J; Kalhor N; Rodriguez J; Bassett R; Wistuba II; Moran CA
Mod Pathol; 2017 Jun; 30(6):826-833. PubMed ID: 28281549
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K
Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277
[TBL] [Abstract][Full Text] [Related]
12. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.
Bi Y; Ren X; Bai X; Meng Y; Luo Y; Cao J; Zhang Y; Liang Z
Eur J Surg Oncol; 2019 Mar; 45(3):353-358. PubMed ID: 30528043
[TBL] [Abstract][Full Text] [Related]
14. Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome.
Tateyama H; Sugiura H; Yamatani C; Yano M
Hum Pathol; 2011 Apr; 42(4):533-40. PubMed ID: 21237498
[TBL] [Abstract][Full Text] [Related]
15. Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses.
Ishihara S; Okada S; Ogi H; Kodama Y; Shimomura M; Tsunezuka H; Itoh K; Marx A; Inoue M
Lung Cancer; 2020 Jul; 145():40-47. PubMed ID: 32402921
[TBL] [Abstract][Full Text] [Related]
16. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.
Katsuya Y; Horinouchi H; Asao T; Kitahara S; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Watanabe S; Tsuta K; Ohe Y
Lung Cancer; 2016 Sep; 99():4-10. PubMed ID: 27565906
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors.
Bedekovics J; Beke L; Mokanszki A; Szilagyi S; Mehes G
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):1-9. PubMed ID: 30499814
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma.
Guo W; Zhang F; Shao F; Wang P; Li Z; Yang X; He Z; Shi S; Gao Y; He J
Hum Pathol; 2019 Feb; 84():291-298. PubMed ID: 30296523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
